Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover

Soleno Therapeutics voluntarily withdrew its European marketing application for its rare metabolic disorder drug after acquirer Neurocrine elected to sharpen focus on the U.S. market. The move removes a near-term EU commercialization pathway and narrows international upside for the asset, though it may reduce near-term regulatory and launch costs under Neurocrine's U.S.-centric strategy.

Analysis

Soleno Therapeutics voluntarily withdrew its European marketing application for its rare metabolic disorder drug after acquirer Neurocrine elected to sharpen focus on the U.S. market. The move removes a near-term EU commercialization pathway and narrows international upside for the asset, though it may reduce near-term regulatory and launch costs under Neurocrine's U.S.-centric strategy.